

Eastbourne District General Hospital

Kings Drive Eastbourne East Sussex BN21 2UD

30th July 2025

FOI REF: 25/499

Tel: 0300 131 4500 Website: www.esht.nhs.uk

FREEDOM OF INFORMATION ACT

I am responding to your request for information under the Freedom of Information Act. The answers to your specific questions are as follows:

I am researching the incidence and treatment of endometrial cancer. I would greatly appreciate if you could answer the following questions.

1) Does your trust provide SACT (systemic anti-cancer therapy) treatments for endometrial cancer? If not, which other trust do you refer endometrial cancer patients to for SACT treatments?

Yes.

2) How many patients were treated for endometrial cancer (any stage) in the past three months with the following treatments:

	 Dostarlimab (Jemperli) Dostarlimab (Jemperli) AND Chemotherapy Hormone therapy (Progesterone or Letrozole) Pembrolizumab (Keytruda) monotherapy Lenvatinib + Pembrolizumab (Lenvima +Keytruda) Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) Any other SACT Any other Chemotherapy Durvalumab with platinum-based chemotherapy Pembrolizumab with platinum-based chemotherapy 	2 1 0 0 1 3 0 0 0 0
3)	In the past three months, how many patients were treated for recurrent endometrial cancer after having previously received platinum-based chemotherapy?	2

4) In the past three months, how many patients were treated for endometrial cancer with the following as first line treatments:

•	Dostarlimab (Jemperli) AND Chemotherapy	1
•	Durvalumab with platinum-based chemotherapy	0
•	Pembrolizumab with platinum-based chemotherapy	0
•	Hormone therapy (Progesterone or Letrozole)	0
•	Platinum-based chemotherapy (monotherapy or combination	
	with taxanes, anthracyclines, cyclophosphamide)	2
•	Any other SACT	0
•	Any other chemotherapy	0

5) Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part?

The Trust does not have any clinical trials open for endometrial cancer.

If I can be of any further assistance, please do not hesitate to contact me.

Should you be dissatisfied with the Trust's response to your request, you have the right to request an internal review. Please write to the Freedom of Information Department (<u>eshtr.foi@nhs.net</u>), quoting the above reference, within 40 working days. The Trust is not obliged to accept an internal review after this date.

Should you still be dissatisfied with your FOI request, you have the right of complaint to the Information Commissioner at the following address:

The Information Commissioner's Office Wycliffe House Water Lane Wilmslow Cheshire SK9 5AF

Telephone: 0303 123 1113

Yours sincerely

Freedom of Information Department esh-tr.foi@nhs.net